SGLT2 inhibitors were associated with a quarter less retinopathy progression than other diabetes drugs

Design

Meta-analysis and meta-regression of 16 comparative studies

Population

1,785,409 people with diabetes on SGLT2 inhibitors or other glucose-lowering drugs

Primary outcome

Diabetic retinopathy and macular oedema progression

Effect

DR progression RR 0.77 (0.72-0.82); DME progression RR 0.75 (0.69-0.82)

This meta-analysis pooled 16 studies of 1,785,409 people with diabetes comparing SGLT2 inhibitors with DPP-4 inhibitors, GLP-1 receptor agonists, sulfonylureas and other glucose-lowering drugs.

SGLT2 inhibitors were associated with less diabetic retinopathy progression (RR 0.77, 95% CI 0.72-0.82) and less macular oedema progression (RR 0.75, 0.69-0.82), against all comparators and each class. The benefit was largest against sulfonylureas. Where 20% of a cohort progressed, the absolute reduction was about 4 percentage points.

Ophthalmologists rarely influence the glucose-lowering drug, but the eye clinic is often where retinopathy progression is noticed. This gives a reason to raise drug choice in the letter back to the physician.

The data are mainly observational, so the association may partly reflect who is prescribed newer drugs.

• When retinopathy or macular oedema progresses, mention SGLT2 inhibitors in the letter to the diabetologist.
• Note that the advantage was clearest over sulfonylureas, which remain widely used in India.
• Remember that rapid HbA1c reduction with any agent can transiently worsen retinopathy.
• Keep screening intervals unchanged; drug choice does not replace examination.

Why it matters

Choice of glucose-lowering drug, not only glucose control, may affect how fast retinopathy advances.

Don't overread it

Most included studies were observational; this does not prove SGLT2 inhibitors protect the retina.

The statistics, in plain English

A relative risk of 0.77 means about 23% fewer progressions. The absolute benefit depends on baseline risk, so in a low-risk population the difference is small, while in patients with established retinopathy it is more meaningful.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.